Ahren Innovation Capital

Ovo Labs is developing therapeutics that boost egg quality to enhance IVF success, technology aims to extend the timeline when the chances of conception are high.

Constructive Bio is a biotechnology company focused on genome rewriting to unlock new possibilities in bioprocesses and biopharmaceuticals. The company transforms living cells into biofactories, producing sustainable materials and therapeutics. By harnessing advanced technologies, Constructive Bio creates virus-resistant organisms and biosynthesizes a range of enzymes, pharmaceuticals, and biomaterials. This innovative approach allows clients to reprogram genetic codes, enabling the creation of natural molecules that were previously inaccessible through conventional biology. Through its unique capabilities, Constructive Bio aims to lead the development of the next generation of sustainable solutions in the life sciences.

ZOE is a personalized nutrition company that focuses on improving individual health through a comprehensive understanding of the complex relationships between food, lifestyle, and health. It operates the world's largest nutrition-science study, as well as the ZOE Health Study, which initially addressed the impacts of COVID-19. The company offers at-home testing kits that assess gut health, blood fat, and blood sugar responses, providing personalized dietary recommendations based on individual reactions to food. Users receive tailored advice through an integrated mobile application, which includes food scores and guidance for making healthier dietary choices over a four-week period. ZOE's research is grounded in the understanding that gut bacteria significantly influence health, and its findings have been published in prestigious peer-reviewed journals. Through its innovative approach, ZOE aims to empower individuals to enhance their well-being and adopt healthier lifestyles.

Mentee Robotics develops AI-powered humanoid robots that integrate robotics, sensing, and artificial intelligence to perform a variety of tasks in both household and warehouse settings. These robots are designed with human-like dexterity and perception, allowing them to adapt to different environments and effectively engage in activities such as lifting, carrying heavy objects, organizing, and packing. By enhancing productivity and streamlining daily operations, Mentee Robotics aims to improve efficiency in both domestic and industrial contexts through the use of advanced technology and natural human interaction.

Sunfire is a company that specializes in developing and manufacturing systems for renewable industrial gas and fuel production. It focuses on creating substitutes for fossil fuels, such as mineral oil and natural gas, through innovative technologies like electrolyzers and solid oxide cells. These systems convert renewable electrical energy from sources like wind farms, hydropower plants, and photovoltaic systems into fuels and gases, including renewable hydrogen and syngas. By enabling the chemical, fuel, and steel industries to transition away from fossil energy, Sunfire aims to provide sustainable energy solutions that are available whenever needed, thus integrating renewable energy into existing infrastructures.

Mogrify has developed a proprietary suite of technologies aimed at advancing patient care through innovative in vivo reprogramming therapies. The company's platforms, MOGRIFY and epiMOGRIFY, utilize a systematic big-data approach to direct cellular reprogramming, leveraging next-generation sequencing and gene regulatory data to predict the necessary transcription and growth factors for generating any target human cell type from various sources. This technology enhances existing stem cell programming methods or allows for direct transdifferentiation between mature cell types. Mogrify focuses on creating functional cell types for applications in ophthalmology, otology, and other degenerative diseases, addressing critical challenges related to efficacy, safety, and scalability in cell therapy. Positioned within a regenerative medicine market projected to reach $150 billion by 2028, Mogrify is commercializing its technology through in vivo therapy development, co-development partnerships, and exploration of additional therapeutic and non-therapeutic applications.

ZOE is a personalized nutrition company that focuses on improving individual health through a comprehensive understanding of the complex relationships between food, lifestyle, and health. It operates the world's largest nutrition-science study, as well as the ZOE Health Study, which initially addressed the impacts of COVID-19. The company offers at-home testing kits that assess gut health, blood fat, and blood sugar responses, providing personalized dietary recommendations based on individual reactions to food. Users receive tailored advice through an integrated mobile application, which includes food scores and guidance for making healthier dietary choices over a four-week period. ZOE's research is grounded in the understanding that gut bacteria significantly influence health, and its findings have been published in prestigious peer-reviewed journals. Through its innovative approach, ZOE aims to empower individuals to enhance their well-being and adopt healthier lifestyles.

Ambi Robotics is an artificial intelligence and robotics company founded in 2018 and based in Berkeley, California. The company focuses on developing advanced AI-powered robotic systems aimed at enhancing e-commerce operations and simplifying supply chain processes. Ambi Robotics offers a range of innovative solutions, including a robotic put wall, a configurable modular kitting line, and a sophisticated robot operating system that utilizes simulation-to-reality technology. These systems are designed to improve operational accuracy and efficiency while helping clients reduce costs, ultimately allowing human workers to focus on more complex tasks.

Constructive Bio is a biotechnology company focused on genome rewriting to unlock new possibilities in bioprocesses and biopharmaceuticals. The company transforms living cells into biofactories, producing sustainable materials and therapeutics. By harnessing advanced technologies, Constructive Bio creates virus-resistant organisms and biosynthesizes a range of enzymes, pharmaceuticals, and biomaterials. This innovative approach allows clients to reprogram genetic codes, enabling the creation of natural molecules that were previously inaccessible through conventional biology. Through its unique capabilities, Constructive Bio aims to lead the development of the next generation of sustainable solutions in the life sciences.

Phaidra, Inc. is an AI solutions provider based in Seattle, Washington, founded in 2019. The company specializes in developing artificial intelligence-powered control systems tailored for large industrial facilities. Phaidra's technology analyzes vast amounts of sensor data to create intelligent agents that optimize complex operations. This virtual plant operator enhances the performance of mission-critical facilities by improving energy efficiency, stability, and sustainability. Through its closed-loop AI control service, Phaidra enables operations teams to achieve significant operational improvements, thereby maximizing yield and enhancing safety within industrial environments.

AI21 Labs, founded in 2017 and based in Tel Aviv-Yafo, Israel, specializes in developing generative artificial intelligence and large language models. The company creates tools designed to enhance the understanding and generation of natural language, effectively transforming how users read and write. Its AI-driven writing companion captures real intelligence, rephrasing text to convey precise meanings while providing summaries that aid in comprehension. These innovations empower users to analyze and visualize complex information more efficiently, facilitating a deeper understanding of abstract knowledge structures. Through the application of deep learning and computer vision algorithms, AI21 Labs aims to significantly improve the efficiency of reading and writing processes.

Bitfount is a platform designed for federated data science and artificial intelligence, allowing organizations to collaborate on data without the need to share it directly. Utilizing federated learning and various privacy-preserving technologies, Bitfount facilitates the formation of data consortia and the licensing and training of advanced AI models. This approach enables data providers, data scientists, and governance teams to work together effectively while maintaining strict privacy standards and ensuring data quality. Through its innovative solutions, Bitfount aims to enhance collaborative efforts in data analysis and machine learning across different sectors.

Heirloom specializes in direct air capture technology aimed at enhancing the natural absorption of carbon dioxide from the atmosphere. The company's innovative system accelerates the ability of limestone to capture CO2, allowing for its permanent storage underground. By operating on renewable energy, Heirloom's technology promotes carbon capture and utilization at a large scale, with the goal of removing significant amounts of atmospheric CO2. This approach not only minimizes secondary impacts but also supports clients in restoring the atmosphere through natural processes.

OxDX is a spinout that combines the power of single-molecule fluorescent microscopy with machine learning to identify pathogens in under a minute. They use a universal labelling system to light up everything in our sample, image the sample using super-resolution fluorescence microscopy, and analyse the images in our neural network.

Micropsi Industries GmbH is a robotics software company based in Berlin, Germany, founded in 2014. The company specializes in developing advanced machine learning solutions for robotics and process control. Its flagship product, MIRAI, is an AI-based, sensor-driven robot control system designed for complex assembly tasks. MIRAI enables robots to perform movements that adapt to subtle environmental changes detected by cameras and force sensors. Unlike traditional programming methods, MIRAI's skills are acquired through demonstration, correction, and repetition, allowing users to create robotic capabilities without needing to write code. This innovative approach enhances productivity, ergonomics, and resilience in various industrial applications. The company is supported by notable investors, including Vito Ventures and coparion, as well as experienced business angels from Munich and Berlin.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.

ZOE is a personalized nutrition company that focuses on improving individual health through a comprehensive understanding of the complex relationships between food, lifestyle, and health. It operates the world's largest nutrition-science study, as well as the ZOE Health Study, which initially addressed the impacts of COVID-19. The company offers at-home testing kits that assess gut health, blood fat, and blood sugar responses, providing personalized dietary recommendations based on individual reactions to food. Users receive tailored advice through an integrated mobile application, which includes food scores and guidance for making healthier dietary choices over a four-week period. ZOE's research is grounded in the understanding that gut bacteria significantly influence health, and its findings have been published in prestigious peer-reviewed journals. Through its innovative approach, ZOE aims to empower individuals to enhance their well-being and adopt healthier lifestyles.

Adrestia Therapeutics Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing therapeutics aimed at restoring biological balance in damaged, diseased, and dying cells. Founded in 2017, the company specializes in synthetic rescue, a method that decodes the complexity of genetic networks to identify innovative treatment approaches for various diseases. Adrestia Therapeutics provides basic research, applied research, and experimental development services to advance its mission in the biotechnology industry.

Nu Quantum Ltd is a company focused on developing quantum photonics hardware and infrastructure essential for scaling quantum computers. Founded in 2018 and based in Cambridge, United Kingdom, the company specializes in creating solutions that interconnect quantum computing cores into large distributed clusters. Its offerings include photon sources and detectors, as well as systems for quantum cryptography that enable secure key exchanges. Nu Quantum is also engaged in producing nano-engineered materials that facilitate light generation at the quantum level and ultra-sensitive light detection. By partnering with leading quantum computing companies, governments, and research institutions, Nu Quantum aims to advance the development of entangled qubit networks and accelerate the creation of multi-core quantum supercomputers and quantum data centers.

Rockley Photonics Limited is a London-based company founded in 2013 that specializes in silicon photonics for various applications. The company develops a comprehensive range of photonic integrated circuits, sensors, and full-stack solutions aimed at high-volume markets. Rockley's technology is designed for next-generation sensing platforms, including mobile health monitoring and machine vision, as well as for high-speed data communications. By focusing on integrated optical modules, supporting electronics, software, and AI platforms, Rockley aims to establish a strong presence in dynamic and rapidly growing sectors. The company envisions photonics becoming as ubiquitous as microelectronics, leveraging its versatile platform to address diverse market needs.

Graphcore Limited is a hardware systems company that specializes in developing intelligent processing units (IPUs) tailored for artificial intelligence and machine learning applications. Founded in 2016 and headquartered in Bristol, United Kingdom, the company offers products such as IPU-Accelerator cards, which enhance server performance for machine learning tasks, and IPU-Appliance systems that improve inference capabilities for various users. Graphcore's innovative IPU architecture allows developers to run existing machine learning models significantly faster, facilitating the deployment of advanced AI solutions across diverse servers and software environments. In addition to its Bristol headquarters, Graphcore has locations in Palo Alto, London, Oslo, and Beijing, expanding its global presence in the AI technology sector.

Nu Quantum Ltd is a company focused on developing quantum photonics hardware and infrastructure essential for scaling quantum computers. Founded in 2018 and based in Cambridge, United Kingdom, the company specializes in creating solutions that interconnect quantum computing cores into large distributed clusters. Its offerings include photon sources and detectors, as well as systems for quantum cryptography that enable secure key exchanges. Nu Quantum is also engaged in producing nano-engineered materials that facilitate light generation at the quantum level and ultra-sensitive light detection. By partnering with leading quantum computing companies, governments, and research institutions, Nu Quantum aims to advance the development of entangled qubit networks and accelerate the creation of multi-core quantum supercomputers and quantum data centers.

Mogrify has developed a proprietary suite of technologies aimed at advancing patient care through innovative in vivo reprogramming therapies. The company's platforms, MOGRIFY and epiMOGRIFY, utilize a systematic big-data approach to direct cellular reprogramming, leveraging next-generation sequencing and gene regulatory data to predict the necessary transcription and growth factors for generating any target human cell type from various sources. This technology enhances existing stem cell programming methods or allows for direct transdifferentiation between mature cell types. Mogrify focuses on creating functional cell types for applications in ophthalmology, otology, and other degenerative diseases, addressing critical challenges related to efficacy, safety, and scalability in cell therapy. Positioned within a regenerative medicine market projected to reach $150 billion by 2028, Mogrify is commercializing its technology through in vivo therapy development, co-development partnerships, and exploration of additional therapeutic and non-therapeutic applications.

6D.ai specializes in developing application programming interfaces (APIs) for the augmented reality (AR) industry, focusing on creating an AR cloud platform. Founded in 2017 and headquartered in San Francisco, California, the company utilizes smartphone cameras and mobile sensors to generate real-time, three-dimensional semantic maps of the environment. Its technology allows for infinite scale and real-time 3D reconstruction, enabling developers to create engaging applications that interact seamlessly with the physical world. By crowd-sourcing environmental data, 6D.ai constructs dense meshes that facilitate multi-user AR experiences and enhance 3D mapping capabilities. As of March 31, 2020, 6D.ai operates as a subsidiary of Niantic, Inc.

Mogrify has developed a proprietary suite of technologies aimed at advancing patient care through innovative in vivo reprogramming therapies. The company's platforms, MOGRIFY and epiMOGRIFY, utilize a systematic big-data approach to direct cellular reprogramming, leveraging next-generation sequencing and gene regulatory data to predict the necessary transcription and growth factors for generating any target human cell type from various sources. This technology enhances existing stem cell programming methods or allows for direct transdifferentiation between mature cell types. Mogrify focuses on creating functional cell types for applications in ophthalmology, otology, and other degenerative diseases, addressing critical challenges related to efficacy, safety, and scalability in cell therapy. Positioned within a regenerative medicine market projected to reach $150 billion by 2028, Mogrify is commercializing its technology through in vivo therapy development, co-development partnerships, and exploration of additional therapeutic and non-therapeutic applications.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycles, which are synthetic short peptides designed to stabilize their structural geometry through two loops. The company primarily targets oncology indications with significant unmet medical needs. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate currently undergoing Phase I/IIa clinical trials aimed at tumors expressing Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies for Nectin-4. Additionally, Bicycle Therapeutics is developing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to advance programs in areas like anti-infectives and cardiovascular health. Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.

Adrestia Therapeutics Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing therapeutics aimed at restoring biological balance in damaged, diseased, and dying cells. Founded in 2017, the company specializes in synthetic rescue, a method that decodes the complexity of genetic networks to identify innovative treatment approaches for various diseases. Adrestia Therapeutics provides basic research, applied research, and experimental development services to advance its mission in the biotechnology industry.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycles, which are synthetic short peptides designed to stabilize their structural geometry through two loops. The company primarily targets oncology indications with significant unmet medical needs. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate currently undergoing Phase I/IIa clinical trials aimed at tumors expressing Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies for Nectin-4. Additionally, Bicycle Therapeutics is developing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to advance programs in areas like anti-infectives and cardiovascular health. Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.